Navigation Links
Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
Date:1/19/2009

BASEL, Switzerland, January 19 /PRNewswire-FirstCall/ --

- Tamiflu Remains Fully Effective Against 94 Percent of Circulating Influenza Viruses in Europe

Latest surveillance data coming through the European Centre for Disease Prevention and Control (ECDC) from virologists and clinicians indicates that the influenza A(H3N2) virus is the predominant strain in Europe so far this season. Based on the data published by ECDC Roche confirms that the oral antiviral Tamiflu (oseltamivir) is fully active against influenza A(H3N2) and influenza B, which currently comprise 94 percent of circulating viruses in Europe this year.(1)

Tamiflu resistance reported in the 2008-2009 influenza seasons is confined to H1N1. No resistance has been seen with other circulating seasonal viruses - H3N2 and influenza B.

"Recent media reporting has elevated awareness of the H1N1 seasonal resistance seen this year in the United States and the Far East. However, in Europe the picture is different with H3N2 being the dominant strain so far. The circulating H3N2 viruses, which often cause a more severe illness than H1N1, are sensitive to oseltamivir, which means that oseltamivir will be active against the vast majority of influenza infections in Europe this season, if current trends continue," comments Prof Albert Osterhaus, Head of Virology, Erasmus Medical Centre, Rotterdam. "It is important that doctors understand that oseltamivir remains an effective treatment for patients across Europe."

Vaccines are considered first line in the management of seasonal influenza, however, people who show symptoms or have been in close contact with an infected person may require more immediate intervention, such as Tamiflu, which can rapidly treat and prevent influenza.

European surveillance data

The ECDC reports that in the 2008-2009 season, influenza activity is increasing rapidly acr
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
4. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
5. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
6. DaVita Launches Flu Fighter Program in Support of National Influenza Week
7. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
8. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
9. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
10. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... continuous operation up to 1500 bar. The sanitary design gauge of the NS2006L ... contamination. , The Pony™ NS2006L homogenizer is an ideal solution for the processing ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... UCT Specialties LLC is now,offering their new Product ... in research and development and with input from chemists ... years, each guide is,designed to illustrate and explain the ... it represents., With thousands of calls and monthly ...
... 12 General Research Laboratory,Inc. (GRL) and ... are,advancing their partnership initiated in July 2007 ... products, following the successful,identification of siRNA inhibitors ... of in silico and in vitro studies, ...
... Corporation,(Nasdaq: VOLC ), a leading provider of ... to enhance the diagnosis and,treatment of coronary and ... participating in the Cowen and Company 28th Annual ... presentation by Scott Huennekens, president and chief executive,officer, ...
Cached Biology Technology:UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 3Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 2
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... A first of its kind combination of experiment ... National Laboratory is providing a close-up look at the ... component of plant cell walls, aggregates to form clumps, ... The exact shape and structure of the aggregates, however, ...
... Palo Alto, CA Although scientists have been able to ... a context for associating the proteins encoded in genes ... underlying plant physiology and ecologyespecially in regard to photosynthesisa ... list of proteins encoded in the genomes of plants ...
... International Osteoporosis Foundation (IOF) in collaboration with the European ... burden of fractures in Europe has been vastly underestimated. ... and Sweden alone, an estimated 2.5 million new ... 280 fractures per hour. It also showed an astounding ...
Cached Biology News:ORNL neutrons, simulations reveal details of bioenergy barrier 2What makes a plant a plant? 2Landmark report reveals immense burden of osteoporotic fractures in Europe 2
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
... Immunogen: Synthetic peptide derived from the ... rat ZO-1. Specificity: Specific for the ... Reactivity: Human Dog Rat Mouse (positive ... frozen mouse liver heart blood vessel and ...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: